X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12) 12
humans (11) 11
drug therapy, combination (9) 9
male (9) 9
abt-450/r-ombitasvir (8) 8
adult (8) 8
anilides - administration & dosage (8) 8
antiviral agents - administration & dosage (8) 8
carbamates - administration & dosage (8) 8
pharmacology & pharmacy (8) 8
female (7) 7
macrocyclic compounds - administration & dosage (7) 7
middle aged (7) 7
ribavirin (7) 7
anilides - pharmacokinetics (6) 6
antiviral agents - pharmacokinetics (6) 6
carbamates - pharmacokinetics (6) 6
dasabuvir (6) 6
ritonavir - administration & dosage (6) 6
young adult (6) 6
aged (5) 5
antiviral agents (5) 5
drug interactions (5) 5
hepatitis c, chronic - drug therapy (5) 5
macrocyclic compounds - pharmacokinetics (5) 5
ritonavir - pharmacokinetics (5) 5
uracil - analogs & derivatives (5) 5
antiviral agents - adverse effects (4) 4
antiviral agents - therapeutic use (4) 4
chronic hepatitis-c (4) 4
drug-drug interactions (4) 4
genotype 1 (4) 4
hcv (4) 4
hepatitis (4) 4
hepatitis c (4) 4
hepatitis c virus (4) 4
ribavirin - administration & dosage (4) 4
ritonavir (4) 4
adolescent (3) 3
anilides - adverse effects (3) 3
anilides - therapeutic use (3) 3
area under curve (3) 3
carbamates - adverse effects (3) 3
carbamates - therapeutic use (3) 3
chemistry (3) 3
drug therapy (3) 3
hepacivirus - genetics (3) 3
hepatitis c, chronic - virology (3) 3
human necessities (3) 3
hygiene (3) 3
in-vitro (3) 3
internal medicine (3) 3
liver cirrhosis (3) 3
macrocyclic compounds - adverse effects (3) 3
macrocyclic compounds - therapeutic use (3) 3
medical or veterinary science (3) 3
metallurgy (3) 3
ombitasvir (3) 3
organic chemistry (3) 3
paritaprevir (3) 3
peptides (3) 3
pharmacokinetics (3) 3
pharmacology/toxicology (3) 3
preparations for medical, dental, or toilet purposes (3) 3
sulfonamides - administration & dosage (3) 3
sulfonamides - pharmacokinetics (3) 3
uracil - administration & dosage (3) 3
uracil - pharmacokinetics (3) 3
administration, oral (2) 2
analysis (2) 2
anilides - blood (2) 2
anilides - pharmacology (2) 2
antiviral agents - blood (2) 2
antiviral agents - pharmacology (2) 2
calcineurin inhibitors (2) 2
carbamates - blood (2) 2
carbamates - pharmacology (2) 2
care and treatment (2) 2
cirrhosis (2) 2
clinical trials, phase ii as topic (2) 2
clinical trials, phase iii as topic (2) 2
combination (2) 2
dosage and administration (2) 2
drug dosages (2) 2
epidemiology (2) 2
gastroenterology & hepatology (2) 2
genotype & phenotype (2) 2
healthy volunteers (2) 2
hepacivirus - isolation & purification (2) 2
hepatitis c - drug therapy (2) 2
infections (2) 2
infectious diseases (2) 2
interferon-free therapy (2) 2
liver transplantation (2) 2
macrocyclic compounds - pharmacology (2) 2
management (2) 2
medicine & public health (2) 2
microbiology (2) 2
models, biological (2) 2
ombitasvir/paritaprevir/ritonavir (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MULTICENTER | VIRUS-INFECTION | TELAPREVIR | THERAPY | DASABUVIR | HEPATITIS-C RECURRENCE | GRAFT | RIBAVIRIN | PEGINTERFERON-ALPHA-2B | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 10/2017, Volume 56, Issue 10, pp. 1103 - 1113
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 3/2016, Volume 55, Issue 3, pp. 275 - 295
Journal Article
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 01/2016, Volume 60, Issue 1, pp. 105 - 114
Journal Article
Journal of Infection, ISSN 0163-4453, 2014, Volume 70, Issue 2, pp. 197 - 205
Summary Objectives To examine the safety and efficacy of ombitasvir and ABT-450 with ritonavir (ABT-450/r) ± ribavirin (RBV) in treatment-naïve, non-cirrhotic... 
Infectious Disease | HCV genotype 2 | HCV genotype 3 | SVR24 | SVR12 | Hepatitis C virus | Sustained virologic response | Interferon-free therapy | SVR | INFECTIOUS DISEASES | ABT-450/R-OMBITASVIR | SOFOSBUVIR | COMBINATION | LEDIPASVIR | HEPATITIS-C VIRUS | PEGINTERFERON ALPHA-2B | DASABUVIR | CIRRHOSIS | INTERFERON PLUS RIBAVIRIN | EPIDEMIOLOGY | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Macrocyclic Compounds - pharmacology | Ribavirin - administration & dosage | Adult | Female | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Carbamates - pharmacology | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Anilides - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Anilides - pharmacology | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Ribavirin - pharmacology | Genetic aspects | Health aspects | Liver cirrhosis | Ribavirin
Journal Article
Journal Article
European Journal of Drug Metabolism and Pharmacokinetics, ISSN 0378-7966, 4/2017, Volume 42, Issue 2, pp. 333 - 339
Ombitasvir, paritaprevir (given with low-dose ritonavir), and dasabuvir are direct-acting antivirals (DAAs) used with or without ribavirin for the treatment of... 
Pharmaceutical Sciences/Technology | Medical Biochemistry | Biomedicine | Human Physiology | Pharmacology/Toxicology | Pharmacy | PHARMACOLOGY & PHARMACY | ABT-450/R-OMBITASVIR | ANTIVIRAL THERAPY | TRANSPORTER EXPRESSION | CIRRHOSIS | CHRONIC HEPATITIS-C | Antiviral Agents - pharmacokinetics | Area Under Curve | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Carbamates - pharmacokinetics | Kidney Function Tests | Dose-Response Relationship, Drug | Young Adult | Clinical Trials, Phase III as Topic | Uracil - administration & dosage | Ribavirin - administration & dosage | Ribavirin - pharmacokinetics | Adult | Female | Renal Insufficiency - complications | Drug Therapy, Combination | Hepacivirus - isolation & purification | Ritonavir - administration & dosage | Macrocyclic Compounds - pharmacokinetics | Genotype | Antiviral Agents - administration & dosage | Sulfonamides - pharmacokinetics | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Models, Biological | Adolescent | Aged | Macrocyclic Compounds - administration & dosage | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Clinical Trials, Phase II as Topic | Uracil - analogs & derivatives
Journal Article
01/2010, ISBN 1124167633
This research developed validated QSPKR and PK-AS models for predicting human systemic PK properties of three, preselected, pharmacological classes of drugs,... 
Pharmacy sciences
Dissertation
07/2015
This application features dose adjustment for drugs co-administered with Compound 1, Compound 2 and/or Compound 3. 
HYGIENE | METALLURGY | PEPTIDES | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | ORGANIC CHEMISTRY | CHEMISTRY | MEDICAL OR VETERINARY SCIENCE | HUMAN NECESSITIES
Patent
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.